Juvenile absence epilepsy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:12:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Juvenile absence epilepsy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Long-Term Safety of Brivaracetam for Children and Young Adults with Childhood or Juvenile Absence Epilepsy https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-brivaracetam-for-children-and-young-adults-with-childhood-or-juvenile-absence-epilepsy/ Wed, 29 Apr 2026 15:01:39 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-brivaracetam-for-children-and-young-adults-with-childhood-or-juvenile-absence-epilepsy/ This clinical trial is focused on studying the long-term safety and tolerability of a medication called brivaracetam in individuals with Childhood Absence Epilepsy or Juvenile Absence Epilepsy. These are types of epilepsy that typically begin in childhood or adolescence and are characterized by brief, sudden lapses in attention or staring spells. The medication being tested, brivaracetam, is available in two forms: a film-coated tablet and an oral solution. It is designed to help manage symptoms associated with these types of epilepsy.

The purpose of the study is to evaluate how safe and well-tolerated brivaracetam is when used over a long period. Participants in the study will receive brivaracetam and will be monitored for any side effects or adverse reactions that may occur during the treatment. The study will also look at how often these side effects lead to participants stopping the medication. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered.

Participants will take brivaracetam for a maximum period of 36 months. Throughout the study, researchers will collect information on any side effects experienced by the participants, including any serious adverse events. This information will help determine the long-term safety of brivaracetam for treating Childhood Absence Epilepsy and Juvenile Absence Epilepsy. The study aims to provide valuable insights into the use of brivaracetam for managing these conditions in children and young adults.

]]> Study of brivaracetam as a treatment for childhood and juvenile absence epilepsy in patients aged 2-25 years https://clinicaltrials.eu/trial/56671/ Wed, 29 Apr 2026 14:29:14 +0000 https://clinicaltrials.eu/trial/56671/ This clinical trial focuses on studying two types of epilepsy: Childhood Absence Epilepsy and Juvenile Absence Epilepsy. These conditions cause brief periods where a person loses awareness of their surroundings and appears to stare blankly into space. The study will test a medication called brivaracetam (oral solution) to see if it works and is safe for patients between 2 and 25 years of age.

The study will examine how well brivaracetam works when used as the only medication for treating these types of epilepsy. Some participants will receive brivaracetam while others will receive a placebo. The study uses a two-stage design, where after the initial treatment period, some participants who responded well to the treatment will enter a withdrawal phase to further confirm the medication’s effectiveness.

The main goal is to find out if brivaracetam can help control absence seizures, which are episodes where a person briefly loses awareness. The study will monitor participants using electroencephalogram (a test that records brain wave patterns) and track how often seizures occur. Throughout the study, researchers will also watch for any side effects to ensure the medication is safe for use in young patients.

]]>